Literature DB >> 7961962

NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter.

N J Combates1, R W Rzepka, Y N Chen, D Cohen.   

Abstract

Revealing the regulatory mechanisms involved in P-glycoprotein expression is important to our understanding of multidrug resistance (MDR) in tumor cells. The MDR1 gene encoding P-glycoprotein contained a promoter sequence (-157 to -125) that was found to be homologous with other mdr gene promoters and that specifically interacted with a nuclear protein. The nuclear protein was identified, using a HeLa lambda gt11 cDNA expression library, to be the transcriptional regulator nuclear factor for interleukin-6 (NF-IL6), a member of the C/EBP family of transcription factors that bound an NF-IL-6-like consensus element 5'-TTTCGCAGT-3'. Furthermore, a glutathione S-transferase fusion protein (10.1-glutathione S-transferase) containing the partial NF-IL6 cDNA was also found to specifically interact with the MDR1 promoter sequence. Co-transfection of an NF-IL6 expression vector with a chloramphenicol acetyltransferase reporter gene driven by 1018 base pairs of MDR1 5'-flanking sequences demonstrated that NF-IL6 trans-activated the MDR1 promoter. This trans-activation was significantly reduced when the NF-IL6 element in the reporter gene construct was deleted or mutated. Identification of NF-IL6 as an important transcriptional regulator and the implications of its potential role in MDR1 gene induction in response to a variety of stimuli are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961962

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein.

Authors:  B Lutterbach; D Sun; J Schuetz; S W Hiebert
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

Review 2.  Molecular pathways: regulation and therapeutic implications of multidrug resistance.

Authors:  Kevin G Chen; Branimir I Sikic
Journal:  Clin Cancer Res       Date:  2012-02-16       Impact factor: 12.531

3.  Nuclear factor kappaB-dependent mechanisms coordinate the synergistic effect of PMA and cytokines on the induction of superoxide dismutase 2.

Authors:  K K Kiningham; Y Xu; C Daosukho; B Popova; D K St Clair
Journal:  Biochem J       Date:  2001-01-01       Impact factor: 3.857

Review 4.  CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases.

Authors:  Cynthia A Zahnow
Journal:  Expert Rev Mol Med       Date:  2009-04-08       Impact factor: 5.600

5.  New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein.

Authors:  Stéphane Labialle; Guila Dayan; Landry Gayet; Dominique Rigal; Joël Gambrelle; Loris G Baggetto
Journal:  Nucleic Acids Res       Date:  2004-07-22       Impact factor: 16.971

6.  Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation.

Authors:  M Piquette-Miller; A Pak; H Kim; R Anari; A Shahzamani
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

7.  Vincristine induction of mutant and wild-type human multidrug-resistance promoters is cell-type-specific and dose-dependent.

Authors:  U Stein; W Walther; R H Shoemaker
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

8.  12-O-tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR1.

Authors:  C McCoy; D E Smith; M M Cornwell
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272

9.  Cytokine-mediated reversal of multidrug resistance.

Authors:  U Stein; W Walther
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

10.  Transcriptional regulation of MDR genes.

Authors:  K W Scotto; D A Egan
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.